We refresh our valuation for Newron Pharmaceuticals in light of the licensing agreements for its lead asset, evenamide, in Japan and South Korea. The €117m deal with EA Pharma in Japan (c 10% of evenamide’s global market) was particularly significant, with an upfront payment of €44m and committed t

17 Jan 2025
Spotlight on evenamide following licensing deals

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Spotlight on evenamide following licensing deals
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
17 Jan 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
8 -
We refresh our valuation for Newron Pharmaceuticals in light of the licensing agreements for its lead asset, evenamide, in Japan and South Korea. The €117m deal with EA Pharma in Japan (c 10% of evenamide’s global market) was particularly significant, with an upfront payment of €44m and committed t